Gefitinib versus Vinorelbine+Cisplatin as Adjuvant Treatment in Stage II-IIIA NSCLC

Gefitinib versus Vinorelbine+Cisplatin as Adjuvant Treatment in Stage II-IIIA NSCLC

User Photo
AnnualMeeting2017

3 years
1,091 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
H. Jack West, MD of Swedish Cancer Institute gives an overview of the use of gefinitib compared to standard chemotherapy (vinorelbine+cisplatin) as adjuvant treatment for patients with non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL. Abstract 8500: Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104)
Up Next Autoplay